Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the immunisation protects vulnerable infants

RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”

The pregnancy vaccine works by stimulating the mother’s body’s defences to generate defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, precisely when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst noting that protection remains possible even if administered later in the third trimester.

• Nearly 85% protection when vaccinated 4 weeks before birth
• Maternal antibodies transferred through placenta safeguard newborns from birth
• Protection possible with two-week gap before premature birth
• Vaccination in third trimester still offers meaningful infant protection

Compelling evidence from recent research

The effectiveness of the pregnancy RSV vaccine has been confirmed through a extensive research programme carried out throughout England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month period, providing strong and reliable evidence of the vaccine’s actual performance. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scale of this research provides healthcare professionals and parents-to-be with confidence in the vaccine’s proven efficacy across different groups and contexts.

The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This stark contrast emphasises the vaccine’s vital importance in protecting against serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.

Study design and parameters

The research reviewed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or small subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology measured actual clinical results rather than laboratory-based settings, providing real-world data of how the vaccine functions when delivered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Understanding RSV and the hazards

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.

The infection triggers inflammation deep within the lungs and airways, making it perilously hard for infected babies to feed and breathe adequately. Parents commonly see their babies struggling visibly, their chests heaving as they work to get adequate oxygen into their weakened respiratory system. Whilst the majority of babies recover with supportive care, a modest yet notable number die from RSV-related complications annually, making vaccination as prevention a critical public health objective for safeguarding the youngest and most vulnerable people in our communities.

• RSV triggers inflammation in lungs, resulting in serious respiratory problems in infants
• Approximately half of infants acquire the virus in their first few months of life
• Symptoms vary between minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
• More than 20,000 UK infants need serious hospital treatment for RSV each year
• A small number of infants die from RSV complications each year in the UK

Uptake rates and expert recommendations

Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women receiving their jab at the ideal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that the timing is essential for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers nearly 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies through the placenta.

The communication from public health bodies remains clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured pregnant women that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.

Regional variations in vaccine uptake

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These geographical variations demonstrate variations in medical facilities, engagement approaches, and local engagement efforts, though the overall statistics demonstrates robust and reliable protection regardless of geographical location.

• NHS trusts launching multiple messaging strategies to reach pregnant women
• Inconsistencies across regions in vaccination coverage levels in different parts of England demand focused enhancement
• Regional health providers modifying schemes to suit community needs and circumstances

Real-world impact and parental perspectives

The vaccine’s outstanding effectiveness translates into concrete gains for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this safeguarding intervention, the 80% decrease in admissions means thousands of infants protected against serious illness. Parents no longer face the distressing scenario of seeing their babies gasping for air or difficulty feeding, symptoms that characterise critical RSV illness. The vaccine has markedly changed the terrain of neonatal respiratory health, providing expectant mothers a proactive tool to safeguard their youngest infants during those crucial first weeks.

For families like that of Malachi, whose acute RSV infection led to severe brain damage, the vaccine’s introduction carries deep personal significance. His mother’s promotion of the jab highlights the profound consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to women in pregnancy navigating their third trimester, converting what was once an inevitable seasonal threat into a controllable health concern.